ARTL: Artelo PEG Multiple
Artelo Biosciences develops endocannabinoid system modulators to combat oncology and neuropathy. Compound synthesis is highly automated via robotics to ensure sterility. The company is currently focusing on publishing clinical trial data for small molecules. The 0.00 metric indicates the status of the ratio between cost and business expansion rates within the price action on the GURU.Markets chart.
Metric breakdowns and analytics for Artelo Biosciences (ARTL)
- share price and expert price forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
- earnings and valuation multiples information:
ARTL - Company Net Income|Expected Net Profit Artelo Biosciences|ARTL - Price to Earnings Ratio|Future Price to Earnings Multiple artelobio.com|ARTL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artelo|ARTL - Operating profit EBITDA|Net earnings per share for the last four quarters Artelo Biosciences|ARTL - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months artelobio.com|ARTL - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Artelo Biosciences
Summary company analytics:Artelo Biosciences Inc.
Investors utilize this ratio to identify undervalued assets where market value does not align with earnings growth rates. The PEG ratio allows for the filtering of overvalued securities, which is critical for Artelo Biosciences (ARTL), as its valuation depends on clinical success in cancer treatment rather than macroeconomic cycles.
Competing companies
INDV: Market Cap to Earnings and Growth Ratio|PEG Multiple COLL (Collegium Pharmaceutical Inc)|PEG Multiple Cronos Corp CRON|CGC - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio HITI (hightideinc.com)|auroramj.com (ACB) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Achieve Life Sciences Inc.|SKYE (Skye Bioscience, Inc.) - PEG Multiple|PEG Multiple Anebulo Pharma|Price/Earnings to Growth Ratio InterCure Ltd. (INCR)|NTRB (nutriband.com) - Growth-Adjusted Payback Ratio|Nasus Pharma - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio IGC (India Globalization Capital)|MIRA Pharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Flora Growth Inc|imcannabis.com (IMCC) - Price/Earnings to Growth Ratio|ADIL (Adial Pharmaceuticals, Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Ensysce Biosciences Inc.|Price to Earnings Adjusted for Growth Rate Titan Pharma TTNP|Price/Earnings to Growth Multiple GNLN (Greenlane Holdings Inc)|INM (InMed) - Growth-Adjusted Payback Ratio|PEG Multiple AKAN (Akanda)|enveric.com - Price/Earnings to Growth Ratio|Bright Green Corp - PEG Multiple|Growth-Adjusted Market Cap to Net Income hempaccoinc.com HPCO
